Acquisition – Talk Bio

AstraZeneca deepens cell therapy expansion with $1B EsoBiotec buyout

1 month ago talkbio0Tagged Acquisition, AstraZeneca, Autoimmune Diseases, Cell Engineering, Cell Therapy, ENaBL Platform, EsoBiotec, in vivo, Neoplasms

AstraZeneca, EsoBiotec, cell therapy, acquisition, ENaBL platform, in vivo cell engineering, oncology, autoimmune diseases

Jazz Pharmaceuticals to Acquire Chimerix for $935 Million, Gaining Promising Brain Tumor Drug Dordaviprone

2 months ago2 months ago talkbio0Tagged Acquisition, Approved, Brain Neoplasms, Chimerix, Diffuse Glioma, Dordaviprone, Jazz, Oncology Pipeline, United States Food and Drug Administration

Jazz Pharmaceuticals, Chimerix, Acquisition, Dordaviprone, Brain tumor, H3 K27M-mutant diffuse glioma, FDA approval, Oncology pipeline

Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger

2 months ago talkbio0Tagged Acelyrin, Acquisition, all-stock, Alumis, Biological Factors, Concentra Biosciences, Immunology, Merger, Transaction

Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction

Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge

2 months ago talkbio0Tagged Acquisition, Eli, Eli Lilly, FXR314, Increase, Inflammatory Bowel Diseases, NR1H4 gene, Organovo, Prices, Programs - Publication Format

Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase

Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation

2 months ago talkbio0Tagged Acquisition, Capital, Carlyle, DKK1 gene, Family Turdidae (organism), Financial Stress, gene therapy, Industry, Private Equity

Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry

AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat

2 months ago talkbio0Tagged Acquisition, Anemia, AstraZeneca, China, Chronic Kidney Diseases, Drug Industry, FibroGen, roxadustat

AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry

Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics, Bolstering Oncology Portfolio

2 months ago talkbio0Tagged Acquisition, Drug Industry, Gomekli, Merck KGaA, Neoplasms, Ogsiveo, SpringWorks

Merck KGaA, SpringWorks Therapeutics, acquisition, oncology, rare diseases, Ogsiveo, Gomekli, pharmaceutical industry

Novartis Acquires Anthos Therapeutics for $925M, Regaining Control of Promising Anticoagulant Abelacimab

2 months ago talkbio0Tagged abelacimab, Acquisition, Anthos, Anticoagulants, Atrial Fibrillation, cardiovascular pipeline, Cerebrovascular accident, Factor XI antibody, Novartis

Novartis, Anthos Therapeutics, acquisition, abelacimab, anticoagulant, Factor XI inhibitor, atrial fibrillation, stroke prevention, cardiovascular pipeline

Merck KGaA in Advanced Negotiations to Acquire SpringWorks Therapeutics

2 months ago talkbio0Tagged Acquisition, biopharmaceutical industry, cancer treatments, Does speak, Merck KGaA, Ogsiveo, SpringWorks

Merck KGaA, SpringWorks Therapeutics, acquisition talks, biopharmaceutical industry, rare diseases, cancer treatments, Ogsiveo

J&J’s Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal

2 months ago talkbio0Tagged Acquisition, Caplyta, Drug Industry, Duato, Intra-Cellular Therapies, Joaquin, Johnson and Johnson, M&A, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, acquisition, neuroscience, CAPLYTA, Joaquin Duato, pharmaceutical industry, M&A